Artificial intelligence has become a familiar tool for commercial teams across healthcare. From writing emails to summarizing meetings, many medical device sales representatives now rely on AI to complete routine administrative work more efficiently. New research suggests those productivity gains may only scratch the surface of what the technology can deliver.
A recent survey of 150 US medical device sales representatives by AcuityMD found that sales professionals using AI were three times more likely to meet or exceed quota than those who were not. The findings point to a growing relationship between AI adoption and commercial success while revealing that many organizations have yet to unlock the technology’s strategic potential.
Only 36% of respondents said they use AI regularly or occasionally in their daily workflow. Despite widespread interest in generative AI, most commercial teams remain in the early stages of adoption, with many focusing on routine productivity rather than revenue-generating insight.
The disconnect highlights an emerging challenge for MedTech manufacturers. Competitive advantage may no longer depend on whether teams use AI but on how they apply it.
AI adoption is improving productivity, but most sales teams remain in the early stages
The survey paints a picture of cautious but growing adoption. Nearly all respondents who use AI reported measurable time savings, with 92% saving at least four hours each week. For sales representatives balancing customer meetings, hospital access requirements, product training and administrative work, recovering several hours each week represents a meaningful operational gain.
Current usage remains heavily focused on routine activities. Email drafting is the most common application, followed by task organization and meeting summaries. These capabilities reduce manual work and allow sales professionals to spend more time with customers.
Productivity gains alone, however, do not fully explain the strong relationship between AI use and quota attainment.
One of the more revealing findings is that most representatives continue to rely on general-purpose AI platforms instead of solutions designed specifically for healthcare and medical device sales. Generic AI tools can summarize information and generate content, but they lack access to the specialized commercial, clinical and provider data that influence purchasing decisions within hospitals and health systems.
The survey also found that representatives meeting or exceeding quota were significantly more likely to have access to employer-provided AI platforms. This suggests that organizational investment, training and integration may be just as important as individual willingness to adopt new technology.
Broader market research points in the same direction. Organizations that embed AI into structured sales processes are reporting stronger commercial outcomes than those treating AI solely as a productivity tool.
The biggest opportunity lies in strategic commercial intelligence rather than automation
Administrative use cases dominate AI adoption today, yet relatively few sales professionals use AI to strengthen commercial decision-making.
Only a small percentage of respondents reported using AI for strategic account research or uncovering new commercial insight. This may represent the largest untapped opportunity within MedTech sales.
Medical device purchasing decisions involve complex clinical, financial and operational considerations. Sales representatives need visibility into physician relationships, procedural volumes, service line expansion, hospital priorities and competitive activity. AI becomes considerably more valuable when it analyzes these variables and identifies opportunities that would otherwise remain hidden.
Instead of simply drafting follow-up emails, AI can help identify physicians increasing procedure volumes, hospitals investing in new specialties or health systems preparing for equipment upgrades. These insights allow commercial teams to prioritize accounts more effectively, allocate territories more strategically and engage customers earlier in the buying cycle.
Purpose-built AI platforms are beginning to combine generative capabilities with proprietary healthcare datasets, giving sales teams recommendations grounded in industry-specific intelligence rather than publicly available information. As these platforms mature, AI shifts from being an assistant that completes tasks to becoming a decision support system that strengthens commercial execution.
For sales leaders, the implication is straightforward. Investment should extend beyond giving employees access to generative AI. The greatest return is likely to come from integrating AI into commercial strategy, customer intelligence and account planning while ensuring teams understand how to use these capabilities effectively.
The latest research suggests AI adoption within medical device sales has reached an important turning point. Early enthusiasm centered on efficiency, helping representatives automate repetitive work and recover valuable selling time. Those benefits remain valuable, but they are unlikely to define long-term competitive advantage.
Organizations that combine AI with proprietary healthcare data, structured sales processes and targeted commercial intelligence appear better positioned to improve sales performance. The technology becomes more than a writing assistant. It becomes a source of strategic insight that supports stronger customer engagement and better-informed commercial decisions.
As adoption accelerates across the MedTech industry, the companies most likely to outperform competitors will not necessarily be those using the most AI. They will be the organizations applying it where commercial decisions have the greatest impact.
Source
